Novartis AG’s best-selling drug and a key new cancer medicine posted disappointing sales last quarter, even as the Swiss drugmaker lifted profit guidance for a third straight quarter. Sales of heart ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

Novartis raised its full-year guidance for the third time this year after higher third-quarter profit and sales topped ...

The MHRA said that Novartis' drug warranted inclusion in the EAMS because "despite different available treatment options, patients with heart failure, especially those with reduced ejection ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

With full confidence in China, where Novartis recorded 17 percent growth last year, one of the fastest among all major ...

Sales of heart failure medication Entresto fell short of expectations, while closely watched cancer drug Pluvicto only beat estimates because of a one-time gain. The results pushed Novartis shares ...

Novartis has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from approving it, though the generic's launch faces ...

Novartis forecasts full-year sales growth ... and volume growth in core indications. Heart failure drug Entresto sales increased 26% to $1.87 billion, a demand-led growth. The drug has increased ...